Safe Care CommitmentGet the latest news on COVID-19, the vaccine and care at Mass General.Learn more
The HEALEY ALS Platform Trial team is launching a new webinar series to enable members of the ALS community to learn about the mechanism of action and science behind each of the drugs currently in testing in the Platform Trial.
Investigational drug pridopidine enters HEALEY ALS Platform Trial. Investigational drug pridopidine enters HEALEY ALS Platform Trial. Key Takeaways • Investigators are testing the potential of pridopidine for the treatment of amyotrophic lateral
Researchers at Mass General to participate in Target ALS Diagnosis Initiative.
Investigational drug SLS-005 (Trehalose) enters HEALEY ALS Platform Trial. Investigational drug SLS-005 (Trehalose) enters HEALEY ALS Platform Trial. Key Takeaways • Investigators are designing a trial of Trehalose for the treatment of ALS in the
The Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital (MGH) awarded the 2nd annual Healey Center International Prize for Innovation in amyotrophic lateral sclerosis (ALS) to Project MinE for developing the largest single disease whole genome sequencing project in the world.
Antiepileptic drug reduces motor neuron excitability in ALS. Antiepileptic drug reduces motor neuron excitability in ALS. Our findings could have important implications for the field of ALS research both by demonstrating the effect of ezogabine on
The 2020 Pete Frates Memorial 5K Run/Walk/Wheel will be held virtually and benefit the Healey Center for ALS at Mass General.
The Sean M. Healey and AMG Center for ALS at Massachusetts General Hospital is proud to offer the Healey Scholars Program, which funds young investigators researching treatments for people living with ALS.
The National Academy of Medicine has elected 100 new members, including Merit Cudkowicz, MD, MSc, Chief of Neurology and Director of the Healey Center for ALS at Mass General.
An experimental medication that was recently shown to slow the progression of the neurodegenerative disease amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease, has now demonstrated the potential to also prolong patient survival.
Research at Massachusetts General Hospital integrates the full spectrum of "bench to bedside" discovery. Laboratory scientists work collaboratively with clinicians to make discoveries and turn them into treatments, diagnostics and devices that improve our quality of life.